We have recently reported that pharmacological inhibition of the AT1R with telmisartan and glucagon-like peptide-1 (GLP-1) agonist inhibits inflammation, fibroblast proliferation, hypertension, and myocardial fibrosis in the experimental setting of Ang II infusion [8,9]. Here, AGT is linked to hypertensive disorder.